Ventricular Tachycardia in Hypertrophic Cardiomyopathy

Definition

Ventricular tachycardia in hypertrophic cardiomyopathy (HCM) is not a single entity. In young patients with myocyte disarray and increased left ventricular mass, the dominant arrhythmia is polymorphic ventricular tachycardia or ventricular fibrillation; sustained monomorphic ventricular tachycardia is less common and usually reflects scar-related re-entry in older patients, dilated-phase HCM, or an apical aneurysm. The distinction matters clinically because monomorphic ventricular tachycardia is mappable and ablatable, whereas polymorphic ventricular tachycardia and ventricular fibrillation are treated with defibrillation and substrate-independent strategies. (sources/hcm-vt-ablation-jacep-2025, rating: high)

Key Concepts

Mechanisms and substrate distribution

Apical aneurysm phenotype

Catheter ablation outcomes

Cohort Patients Acute success Freedom from VT after index After last ablation Follow-up
Meta-analysis (Garg 2023) 68 84.5% 70.2% 82.8% 18.3 ± 11.7 months
Single-centre (Jin 2025) 32 87.5% 62.5% 71.9% median 31 months
Apical aneurysm (Igarashi 2018) 15 100% 86.7% at 12 months — 12 months

Electrical storm in HCM

The HCM-VT literature maps native scar-related circuits in the lateral wall, apical aneurysm, superior basal region, septum and papillary muscle. A lead inserted into HCM myocardium is a different potential substrate: local trauma, fibrosis and mechanical irritation at the insertion site can create or mark a slow-conduction zone. The HCM-VT ablation cohorts do not address lead insertion sites, and the lead-related proarrhythmia literature is separate. A ventricular tachycardia that maps to a lead insertion site rather than to a recognised HCM substrate should therefore be interpreted as lead-associated until proven otherwise; this is the question raised by the present case.

Contradictions / Open Questions

Connections

Sources